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Abstract
Background: Previous studies suggest that electroacupuncture possesses therapeutic benefits for depressive disorders. The
purpose of this study was to determine whether dense cranial electroacupuncture stimulation (DCEAS) could enhance the
antidepressant efficacy in the early phase of selective serotonin reuptake inhibitor (SSRI) treatment of major depressive
disorder (MDD).
Methods: In this single-blind, randomized, controlled study, patients with MDD were randomly assigned to 9-session DCEAS
or noninvasive electroacupuncture (n-EA) control procedure in combination with fluoxetine (FLX) for 3 weeks. Clinical
outcomes were measured using the 17-item Hamilton Depression Rating Scale (HAMD-17), Clinical Global Impression-
severity (CGI-S), and Self-rating Depression Scale (SDS) as well as the response and remission rates.
Results: Seventy-three patients were randomly assigned to n-EA (n=35) and DCEAS (n=38), of whom 34 in n-EA and 36 in
DCEAS group were analyzed. DCEAS-treated patients displayed a significantly greater reduction from baseline in HAMD-17
scores at Day 3 through Day 21 and in SDS scores at Day 3 and Day 21 compared to patients receiving n-EA. DCEAS
intervention also produced a higher rate of clinically significant response compared to n-EA procedure (19.4% (7/36) vs.
8.8% (3/34)). The incidence of adverse events was similar in the two groups.
Conclusions: DCEAS is a safe and effective intervention that augments the antidepressant efficacy. It can be considered as
an additional therapy in the early phase of SSRI treatment of depressed patients.
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Introduction
Although selective serotonin reuptake inhibitors (SSRIs) are the
mainstay in the treatment of depressive disorders, the treatment
outcomes are unsatisfactory [1]. There remains a large portion of
depressed patients who cannot obtain a full remission and
experience relapse and functional impairment [1,2]. Moreover,
the delay in the onset of the action of SSRIs prolongs patients’
suffering and exposes them to great risk of suicide [3]. These
shortcomings have led to a high demand for seeking alternative
strategies that can enhance the antidepressant efficacy of SSRIs
particularly in the early phase of the treatment [4].
Numerous studies and recent meta-analyses have shown that
acupuncture is efficacious for various types of depressive disorders
[5–7]. Although most acupuncture protocols used were developed
from the doctrine of traditional Chinese medicine and empiricism
rather than modern scientific rationale, experimental and clinical
observations have found that electroacupuncture has robust
immediate and short-term effects in alleviating pain, autonomic
dysfunction, sleep, and mood symptoms [8–10]. This rapid effect
is thought to be associated with the fast and direct modulation of
multiple central neurochemical systems, especially the brainstem
adrenalinergic (NA), serotonergic (5-HT) neuronal and hypotha-
lamic neuroendocrine systems [10], which play the principal role
in the pathophysiology of major depression [11]. These are the
reasons to hypothesize that electroacupuncture can serve to
enhance the antidepressant action in the early phase of SSRI
treatment.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29651Dense cranial electroacupuncture stimulation (DCEAS) is a
novel stimulation mode in which electrical stimulation is delivered
on dense acupoints located on the forehead mainly innervated by
the trigeminal nerve, efficiently modulating multiple central
transmitter systems via the trigeminal sensory-brainstem NA and
5-HT neuronal pathways [12]. Several pilot studies have shown
that DCEAS and similar approaches are effective in improving
refractory obsessive-compulsive disorder (OCD) [12], major
depressive disorder (MDD) [13], post-stroke depression [14], and
MDD-associated residual insomnia [15].
Fluoxetine (FLX) is one of the most prescribed SSRIs for major
depression worldwide [16]. This single-blind, randomized, con-
trolled trial was designed to determine whether DCEAS
intervention could produce greater clinical improvement com-
pared to noninvasive electroacupuncture (n-EA) control procedure
in the early phase of FLX treatment of patients with MDD.
Methods
Subjects
This single-blind, randomized, sham-acupuncture controlled
trial was conducted in Department of Psychiatry at Kowloon
Hospital of Hong Kong between August 2009 and March 2011.
The study protocol was approved by Institutional Review Board
(IRB) of the University of Hong Kong/Hospital Authority Hong
Kong West Cluster and registered in www.controlled-trials.com
(ISRCTN88008690). The protocol for this trial and supporting
CONSORT checklist are available as supporting information (see
Checklist S1 and Protocol S1).
Psychiatrists referred outpatients to the study. The inclusion
criteria were: (1) age 25–65 years; (2) DSM-IV diagnosis of MDD
[17]; (3) 17-item Hamilton Rating Scale for Depression (HAMD-
17) score $18 [18]; and (4) Clinical Global Impression-Severity
(CGI-S) score $4 [19]. Subjects were excluded if they had: (1)
unstable medical conditions; (2) suicidal attempts or aggressive
behavior; (3) a history of manic, hypomanic, or mixed episode; (4)
a family history of bipolar or psychotic disorders; (5) a history of
substance abuse within the previous 12 months; (6) investigational
drug treatment in the previous 6 months; (7) current psychotropic
treatment exceed one week; or (8) needle phobia. All participants
gave voluntary, written and informed consent before entering the
trial.
Randomization and blinding
Patients were randomly assigned to either n-EA or DCEAS
treatment at a ratio of 1:1, using a random block scheme from an
automatic computer program (SPSS version II). The assignment
was done in a single-blind manner, in which the random codes
were only known by the acupuncturists (W.W. and M. S.C.). The
validity of the subject-blind design was ensured by sham
acupuncture procedure performed on the forehead acupoints,
which were outside the visual field of the subjects (see below). In
order to minimize the expected effects, patients were not told
about the potential response of control and DCEAS procedure
during random assignment.
Fluoxetine treatment
Unmedicated patients in both groups received orally adminis-
tered FLX for 3 weeks in an open manner. FLX dose was initiated
at 10 mg/day and escalated to an optimal dose within one week
based on individual patients’ response, with a maximum dose of
40 mg/day. Attaining a balance of efficacy and side effects, this
FLX dosing regimen has been widely used in previous studies of
major depression in the Chinese population [20,21]. Those who
were currently treated with FLX for no more than one week
continued their FLX treatment with the same dose. Those who
were currently treated with other psychotropic medications for no
more than one week were required to be switched to the FLX
regimen by gradually withdrawing the drugs within one week in
order to wash out potential ‘‘carryover’’ effects. The information
about the equivalent efficacy of FLX was offered to the patients.
Concomitant use of other psychotropic drugs was not allowed.
Medication compliance was determined by pill count at each study
visit. Patients who required concomitant medications and those
having less than 80% FLX compliance were advised to withdraw
from the study.
DCEAS and n-EA procedure
The patients received 9 sessions of n-EA or DCEAS
intervention (3 sessions per week) during FLX treatment. Electrical
stimulation was delivered on the following 6 matches of forehead
acupoints that are innervated by the trigeminal nerve via inserted
or non-inserted needles (Fig. 1): Baihui (Du-20) and Yintang (EX-
HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right
Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu
(GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).
For DCEAS, disposable acupuncture needles (0.30 mm in
diameter and 25–40 mm in length) were inserted into acupoints
for a depth of 10–30 mm in a direction oblique or parallel to the
surface. To ensure allocation concealment, the inserted needles
were affixed with adhesive tapes so that DCEAS procedure was
identical to control acupuncture procedure. Electrical stimulation
with continuous waves at 2 Hz and constant current and voltage
(9 V) was delivered via an acupuncture stimulation instrument
(Hwarto, SDZ-II) for 30 min (the pulse width could not be
determined in this model instrument). The choice of this
stimulation mode was based on the fact that low frequency could
exert broader effects on central neurochemical systems compared
to high frequency and has been widely introduced into the
treatment of neuropsychiatric disorders [10,22]. The intensity of
stimulation was adjusted to a level at which the patients felt most
comfortable. For n-EA procedure, Streitberger’s noninvasive
acupuncture needles were used [23,24]. Its validity and credibility
have been well demonstrated [23,24]. The needles with blunt tips
were quickly put onto the same acupoints used in DCEAS without
inserting into the skin. The needles were then affixed with plastic
O-rings and adhesive tapes. Electrical stimulation was delivered
with the same parameters as DCEAS. Patients felt the stimulation
via blunt tips touched on the skin.
To ensure consistency in acupuncture procedure, the principal
investigator (Z.J.Z.) provided a training workshop of acupuncture
protocol. Acupuncture intervention was performed by registered
acupuncturists (W.W. and S.C.M.) who had received 5-year
undergraduate training in Chinese medicine and had practiced
Chinese medicine over three years.
Assessment
Treatment outcomes were changes from baseline in the total
score on HAMD-17 [18], CGI-S [19], and the Chinese-version
Self-rating Depression Scale (SDS) [25] at baseline and at day 3, 7,
14, and 21. The secondary outcome measures included treatment
response, defined as $50% reduction at endpoint from baseline on
HAMD-17, and remission, defined as an endpoint HAMD-17
score of #7. Safety and tolerability were assessed using the
Treatment Emergent Symptom Scale (TESS) [19], in which
adverse events were recorded at each visit, including their date and
time of onset, duration, severity, relationship to intervention, and
the action taken.
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A training workshop with video materials was conducted for raters
who might be involved in clinical assessments. An interrater
reliability coefficient (k value) of .0.80 was achieved after the
completion of training workshop. In this study, all assessments
were completed by the same rater (J.L.).
The credibility of n-EA and DCEAS procedure was evaluated
based on Fink et al. method [26] by asking the patients: ‘‘As we
informed you that you had an equal chance of receiving sham or
active acupuncture treatment, which do you think you had
received?’’
Statistical analysis
Based on our recent meta-analysis, a sample size of 70 patients
(n=35 per group) could provide approximately 80% power to
detect an estimated difference in HAMD-17 score of 3 points, with
a set at 0.05 and an estimated standard deviation of 4.5 at the
endpoint of 3-week treatment [5].
Efficacy analyses were performed on the intention-to-treat
population, defined as participants who completed baseline and at
least one evaluation after treatment. Since measure time points
were not balanced, a linear mixed-effects model was preferably
applied to compare treatment outcomes (HAMD-17, CGI-S and
SDS) over time between the two groups. The model was
established using time and group for categorical fixed factors
and random intercepts with scaled identity covariance matrix.
Subject’s age, gender, duration of the illness, number of relapse,
baseline HAMD-17, tolerability and credibility for acupuncture
procedure were treated as covariates. Between-group differences at
each measure time point were examined using Student t-test. The
data was expressed as mean with 95% confidence interval (95%
CI). Student t test was used to compare continuous baseline
variables between the two groups. Categorical variables, including
categorical baseline variables, response and remission rates,
incidence of adverse events, treatment compliance, and credibility,
were analyzed using Chi-square (x
2) test or Fisher exact test if one
or more expected frequencies were less than 5. Statistical
significance was defined as a two-sided P,0.05. The analyses
were performed with SPSS version 16 software (Chicago, IL,
USA).
Results
Disposition and characteristics of patients
Of 188 outpatients referred by psychiatrists for screening, 73
eligible patients were randomly assigned to n-EA (n=35) and
DCEAS (n=38) group; while 63 (86.3%) of them completed the 3-
week assessment. One patient in n-EA group was excluded from
analysis, because she was later found to have cocaine use in the
past year. Two patients in DCEAS group were excluded from
analysis due to a lack of post-baseline assessment. Seventy patients
(34 in n-EA and 36 in DCEAS) were included in data analysis
(Fig. 2).
Baseline characteristics of patients are summarized in Table 1.
The proportion of females assigned to n-EA group was
significantly higher than that in DCEAS group (97.1% vs.
69.4%, P=0.006, Chi-square test). Other baseline variables were
similar in the two groups. Nearly 93% (65/70) patients had
experienced relapses and 66% (46/70) patients had acupuncture
treatment previously. There were only 18.6% (13/70) of patients
receiving psychotropic medication when entering the study. The
compliance with acupuncture and FLX treatment was nearly 95%
in the two groups.
Efficacy
Changes from baseline in score on HAMD-17, CGI-S, and SDS
over time are illustrated in Table 2 and Fig. 3. The analyses based
on linear mixed-effects model revealed highly linear correlations
between measure time points and changes from baseline in score
on HAMD (r
2=0.497 in n-EA group and r
2=0.531 in DCEAS
group, P,0.0001), CGI (r
2=0.400 in n-EA group and r
2=0.381
in DCEAS group, P,0.0001), and SDS (r
2=0.192 in n-EA group
and r
2=0.248 in DCEAS group, P,0.0001). There were
significant differences in the slope and/or intercept between n-
EA and DCEAS groups on HAMD (F=5.938, df=1,336,
P=0.015) and SDS (F=5.885, df=1,336, P=0.016), but not
CGI (F=232, df=1,336, P=0.631). Between-group comparisons
further revealed that DCEAS-treated patients had a significantly
greater reduction in scores on HAMD-17 compared to patients
receiving n-EA procedure at Day 3 through Day 21 (P#0.025).
The significantly greater reduction was also observed in SDS
scores at day 3 (P=0.037) and day 21 (P=0.004).
The response rate in DCEAS group was not significantly
different from that in n-EA group (19.4% (7/36) vs. 8.8% (3/34),
P=0.308, Fisher Exact test). The remission rate was also similar in
the two groups (2.7% (1/36) vs. 2.9% (1/34), P=0.998, Fisher
Exact test).
The average dose of FLX in DCEAS group was similar to that
in n-EA group (23.0163.2 mg/day (mean 6 SD) vs.
23.462.4 mg/day, P=0.599, t-test).
Safety and tolerability
Adverse events occurred in at least 5% of the patients in either
group are listed in Table 3. No significant differences in the
incidence of any adverse events were found between the two
groups. There were 20.6% (7/34) of patients who felt uncomfort-
able in n-EA procedure, but not significantly different from 38.9%
Figure 1. Acupoints used in dense cranial electroacupuncture
stimulation (DCEAS).
doi:10.1371/journal.pone.0029651.g001
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stimulation.
doi:10.1371/journal.pone.0029651.g002
Table 1. Baseline characteristics of patients.
Variables
n-EA
(n=34)
DCEAS
(n=36)
P values
(t or x
2 test)
Female, n (%) 33 (97.1) 25 (69.4) 0.006
Age (yrs)
a 48.269.8 46.369.9 0.414
Duration of MDD (yrs)
a 7.367.1 7.968.0 0.744
No. of previous depressive episodes
a 3.664.4 4.966.1 0.332
No. (%) of patients with first-onset MDD 3 (8.8) 2 (5.5) 0.669
No. (%) of patients with previous psychiatric admission 8 (23.5) 7 (19.4) 0.901
No. (%) of patients with family members having mental illnesses. 9 (26.5) 13 (36.1) 0.800
No. (%) of patients with previous acupuncture treatment
b 22 (64.7) 24 (66.7) 0.937
No. (%) of patients receiving psychotropic medications at study entry
c 6 (17.6) 7 (19.4) 0.909
SSRIs 33
SNRIs 11
Mood stabilizers 1
d 1
Benzodiazepines 22
Baseline HAMD-17 score
a 23.163.6 23.963.8 0.321
Baseline CGI-S
a 4.360.5 4.460.5 0.760
Baseline SDS score
a 40.6614.5 41.9614.0 0.704
aContinuous data are expressed as mean 6 SD.
bAuricular acupuncture was included.
cThe use of medications did not exceed one week.
dOne patient received a combination of SNRIs and mood stabilizers.
n-EA, noninvasive electroacupuncture; DCEAS, dense cranial electroacupuncture stimulation; MDD, major depressive disorder; SSRIs, selective serotonin re-uptake
inhibitors; SNRIs, Serotonin–norepinephrine reuptake inhibitors; HAMD, 17-item Hamilton Rating Scale for Depression; CGI-S, Clinical Global Impression-Severity; SDS,
Self-rating Depression Scale.
doi:10.1371/journal.pone.0029651.t001
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2=1.985, df=1, P=0.159).
Two patients in DCEAS group discontinued due to intolerance of
acupuncture stimulation.
Credibility of sham and DCEAS procedure
There was no significant difference in the credibility rating
between the two groups, with 45.5% (15/33) of patients treated
with n-EA perceiving to have received DCEAS, while 23.5% (8/
34) of patients in DCEAS believed to have n-EA treatment
(x
2=2.665, P=0.103).
Discussion
The present study demonstrated that DCEAS intervention is
effective in augmenting the antidepressant efficacy of FLX in the
treatment of moderate and severe MDD. While the patients in the
two groups had received similar FLX doses during the study,
DCEAS-treated patients exhibited greater improvement on depres-
sive symptoms, as indicated with the significant greater reduction of
HAMD-17 and SDS score at most measure time points, although
the magnitude of the reduction of SGI-S score, the response and
remission rates were not different in the two groups. Moreover, the
greater reduction of both HAMD-17 and SDS was observed as
early as at day 3 after the first session of acupuncture treatment.
Similar resultwasalsopresent atendpoint of threeweeksof DCEAS
intervention. These data suggest that DCEAS intervention
produces a rapid effect in alleviating depressive symptoms in both
clinician-rated (HAMD-17) and self-rated (SDS) measures of
depression. In addition, there were only two DCEAS-treated
patients who discontinued due to intolerance of acupuncture.
DCEAS intervention did not increase the incidence of any adverse
events compared to n-EA control procedure, suggesting that
DCEAS is a tolerable and safe stimulation mode.
While the current study showed the superior antidepressant
efficacy of DCEAS over n-EA procedure when combined with
FLX, several similar trials failed to demonstrate the superior effects
of active acupuncture regimens in reducing depressive symptoms
compared to sham and placebo acupuncture regimens [27–29].
This has raised the argument that the antidepressant benefits of
acupuncture observed may be derived from placebo effects rather
than physiological mechanisms [28]. Nevertheless, the present
study revealed no significant difference in the credibility of the
control and DCEAS procedures, with nearly 46% of n-EA-treated
patients who perceived to have received active procedure, while
24% of DCEAS-treated patients perceived the control procedure,
suggesting that the non-inserted needling stimulation used in the
present study for a control procedure was valid and acceptable. In
fact, previous studies have well demonstrated the high credibility
of the non-inserted needle device [26]. Therefore, it was unlikely
that the antidepressant benefits of DCEAS observed in the present
study were derived from placebo effects.
There are two possible explanations for negative results in the
previous acupuncture studies of major depression [27–29]. Firstly,
unlike the present study that used the non-inserted control
procedure, the previous studies needled at non-meridian-based
acupoints which are located at a certain distances (usually 1–3 cm)
from the meridian-based acupoints [27–29]. Although there seems
to be some differences in the histological profile between the
meridian- and non-meridian-based acupoints [30], it might be
difficult to differentiate the physiological responses induced by
stimulation at the two types of acupoints. Second, relatively few
acupoints were used in the previous studies [27–29]. This may
result in inadequacy of acupuncture stimulation which is believed
to be an important factor associated with negative results of
acupuncture trials [31].
DCEAS was developed mainly based on a neurobiological
rationale. It is well documented that the forehead acupoints
innervated by the trigeminal sensory pathway have intimate
collateral connections with the brainstem reticular formation, in
particular the dorsal raphe nucleus (DRN) [32,33] and the locus
coeruleus (LC) [34–37]. The latter two brain structures are the
major resources of 5-HT and NA neuronal bodies, respectively,
Table 2. Changes in score on depression scales from baseline in MDD patients.
Variables
n-EA (n=34)
(95% CI)
DCEAS (n=36)
(95% CI)
Between-group
difference (95% CI)
Overall
P value
a
Between-group
P value
a
HAMD-17 0.015
Day 3 23.71 (24.34–23.06) 25.97 (26.71–25.23) 2.27 (1.29–3.25) 0.000
Day 7 25.82 (26.46–25.18) 26.97 (27.71–26.23) 1.15 (0.17–2.13) 0.025
Day 14 26.41 (27.05–25.77) 28.44 (29.18–27.70) 2.03 (1.05–3.01) 0.000
Day 21 26.27 (26.90–25.62) 28.66 (29.39–27.91) 2.39 (1.41–3.37) 0.000
CGI-S 0.631
Day 3 20.32 (20.42–20.22) 20.44 (20.54–20.34) 0.12 (20.03–0.27) 0.116
Day 7 20.65 (20.75–20.55) 20.53 (20.63–20.43) 0.12 (20.03–0.27) 0.116
Day 14 20.71 (20.81–20.61) 20.71 (20.81–20.61) 0.00 (20.15–0.15) 1.000
Day 21 20.74 (20.84–20.64) 20.74 (20.84–20.64) 0.00 (20.15–0.15) 1.000
SDS 0.016
Day 3 26.44 (28.48–24.40) 29.76 (212.03–27.49) 3.32 (0.26–6.38) 0.037
Day 7 28.82 (210.86–26.78) 29.12 (211.39–26.85) 0.30 (22.76–3.36) 0.851
Day 14 211.74 (213.78–29.70) 212.38 (214.65–210.11) 0.64 (22.42–3.70) 0.679
Day 21 28.38 (210.42–26.34) 213.06 (215.33–210.79) 4.68 (1.62–7.74) 0.004
aOverall and between-group P values were obtained from linear mixed-effects model analysis and student t-test, respectively.
MDD, major depressive disorder; n-EA, noninvasive electroacupuncture; DCEAS, dense cranial electroacupuncture stimulation; 95% CI, 95% confidence interval; HAMD-
17, 17-item Hamilton Rating Scale for Depression; CGI-S, Clinical Global Impression-Severity; SDS, Self-rating Depression Scale.
doi:10.1371/journal.pone.0029651.t002
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including the prefrontal cortex and the amygdala known to be
heavily involved in the pathogenesis of depressive disorders [38]. A
large body of evidence confirms that the brainstem 5-HT and NA
neuronal systems play a pivotal role in acupuncture modulation of
multiple brain functions, including pain, emotion, sleep, and
visceral information processing [8–10,39]. Neuroanatomical and
neurophysiological studies have demonstrated that electroacupunc-
ture stimulation increases the expression of 5-HT in the DRN [40]
and suppresses the stress-induced increase in neuronal activities of
the LC [41,42]. Neuroimaging studies have also shown that
electroacupuncture stimulationis capable of directly modulating the
activity of the emotion processing-related brain regions [8].
Through the intimate collateral connection from the trigeminal
Figure 3. Mean changes from baseline in score on the 17-item Hamilton Rating Scale for Depression (HAMD-17), Clinical Global
Impression-Severity (CGI-S) and Self-rating Depression Scale (SDS). Data are expressed as mean with 95% confidence interval (95% CI).
* P#0.037: between-group comparison using Student t-test.
doi:10.1371/journal.pone.0029651.g003
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the needling of the forehead acupoints with subsequent electrical
stimulation could robustly elicit afferent acupuncture signals via
biophysical and biochemical reactions at local acupoints and, in
turn, efficiently modulates central 5-HT and NA neuronal functions
[9,10]. On the other hand, like other noninvasive brain stimulation
therapies, such as transcutaneous electrical nerve stimulation
(TENS), repetitive transcranial magnetic stimulation (rTMS), and
electroconvulsive therapy (ECT) [43,44], electrical stimulation was
also directly delivered on the scalp in both control and DCEAS
procedure. This may elicit a transcutaneous and/or transcranial
effect; however, such effect would likely be minimal as the
stimulation intensity used in both n-EA control and DCEAS
procedures was generally much lower than rTMS, ECT, and most
TENS [43,44]. Therefore, we have reason to believe that the
antidepressant efficacy of DCEAS observed in the present study
should be derived mainly from the biophysical and biochemical
effects produced in needling with subsequent electrical stimulation
[45]. This also could explain the superior therapeutic efficacy of
DCEAS over n-EA control procedure.
Several limitations of the present study should be noticed. First,
the study was conducted in a female-dominated sample with a
significant difference in the proportion of female subjects between
the two groups. Epidemiological evidence suggests that women are
more likely to use complementary and alternative medicine (CAM)
and have a higher degree of confidence in CAM efficacy and safety
[46]. Whether similar therapeutic effects of DCEAS could be
achieved in male patients needs to be further investigated. In
addition, as the study was conducted in a single-blind manner,
effects mediated by non-blinded acupuncturists could not be
excluded. Recently, a well-demonstrated control method for
single-blind condition has been introduced and could be considered
in future studies [47]. Second, although DCEAS achieved a
clinically meaningful, over 2-fold difference in the response rate
than the control procedure (19.4% vs. 8.8%), the difference did not
reach statistical significance level. This may be due to the relatively
low response rates in the two groups when compared to other
similar trials, with response rates of 22–80% for active acupuncture
and 39–78% for sham or placebo-treated groups [27–29]. The
relatively low response rate observed in the present study appears to
be related to the short-term (3-week) treatment. As long-term effects
of DCEAS were not evaluated in this study and a majority of
depressed patients may be required for long-term treatment [48],
long-term antidepressant efficacy of DCEAS may deserve to be
further investigated. Finally, although we measured patients’
platelet 5-HT contents at baseline and posttreatment (data not
shown in this report), no significant changes in platelet 5-HT
parameters were observed in DCEAS-treated patients compared to
patients treated with n-EA, suggesting that acupuncture may have
least effects on non-neuronal 5-HT systems. Evaluation of DCEAS
effectsinthe brain5-HT neuronal systemmayhelp gain newinsight
into central mechanisms responsible for DCEAs effects.
Collectively, the present study demonstrates that DCEAS is a
safe and effective intervention in augmenting the antidepressant
efficacy in the early phase of SSRI treatment. As patients with
moderate and severe major depression have a higher risk of suicide
and the worsening of symptoms in the early phase of SSRI
treatment, DCEAS can be considered as an additional treatment
option. The present study guarantees a larger-scale, multi-site trial
to further determine the effectiveness of DCEAS as a viable and
safe non-pharmacological augmentation for depressive disorders.
Supporting Information
Checklist S1 CONSORT Checklist.
(PDF)
Protocol S1 Trial Protocol.
(PDF)
Acknowledgments
We thank the following colleagues at Department of Psychiatry of
Kowloon Hospital for their assistance in patient recruitment: Ka-Lik
Kwan, Chun-Ting Chan, Man-Lui Chan, Chi-Kwan Cheung, Janice
Chik, Lung-Kit Hui, Man-Man Kwan, Chee-Kin Lee, Kwok-Chuen Ng,
Yin-Ting Ng, Ting-Keung Poon, Fu-Yin Tong, Wai-Ching Yan, Kam-
Hing Yeung, Tin-Yan Yeung, Mei-Kuen Frieda Shiu, Cheuk-Kin Tang,
Pui-Shan Tse, Ngar-Fong Lam, See-Cheuk Fu, Chui-Lin Carol Ching,
Ka-Fai Ho, Sau-Lai Tai, Sau-Ming Chan, Yiu-Kwun Law, and Yuk-Kwan
Yvonne Kwong.
Author Contributions
Conceived and designed the experiments: Z-JZ RN Q-RT K-cY.
Performed the experiments: SCM TYJL WW M-TW W-KAT. Analyzed
the data: Z-JZ HKW. Wrote the paper: Z-JZ RN Q-RT K-FC EZ VTW.
Table 3. Adverse events occurred in at least 5% of patients in either group.
Event n-EA (n=34) DCEAS (n=36) x
2 P value
Dizziness 15 (44.1) 11 (30.6) 0.858 0.354
Tiredness 10 (29.4) 15 (41.7) 0.672 0.412
Nausea 10 (29.4) 10 (27.8) 0.013 0.910
Excessive sweating 9 (26.5) 6 (16.7) 1.403 0.236
Headache 8 (23.5) 10 (27.8) 0.018 0.894
Transient tachycardia 8 (23.5) 9 (25.0) 0.018 0.892
Insomnia 7 (20.6) 9 (25.0) 0.024 0.877
Uncomfortable for needling sensation 7 (20.6) 14 (38.9) 1.985 0.159
Vomiting 4 (11.8) 3 (8.3) 0.706
a
Unsteadiness 2 (5.9) 6 (16.7) 0.266
a
Somnolence 2 (5.9) 6 (16.7) 0.266
a
aP values were calculated from Fisher Exact test.
n-EA, noninvasive electroacupuncture; DCEAS, dense cranial electroacupuncture stimulation.
doi:10.1371/journal.pone.0029651.t003
Acupuncture for Depression
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29651References
1. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, et al. (2005) Efficacy and
tolerability of tricyclic antidepressants and SSRIs compared with placebo for
treatment of depression in primary care: a meta-analysis. Ann Fam Med 3:
449–456.
2. Blier P, de Montigny C (1994) Current advances and trends in the treatment of
depression. Trends Pharmacol Sci 15: 220–226.
3. Blier P (2003) The pharmacology of putative early-onset antidepressant
strategies. Eur Neuropsychopharmacol 13: 57–66.
4. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, et al. (2005) Strategies for
producing faster acting antidepressants. Drug Discov Today 10: 578–585.
5. Zhang ZJ, Chen HY, Yip KC, Ng R, Wong VT (2010) The effectiveness and
safety of acupuncture therapy in depressive disorders: systematic review and
meta-analysis. J Affect Disord 124: 9–21.
6. Smith CA, Hay PP, Macpherson H (2010) Acupuncture for depression.
Cochrane Database Syst Rev 20: CD004046.
7. Wang H, Qi H, Wang BS, Cui YY, Zhu L, et al. (2008) Is acupuncture beneficial
in depression: a meta-analysis of 8 randomized controlled trials? J Affect Disord
111: 125–134.
8. Dhond RP, Kettner N, Napadow V (2007) Neuroimaging acupuncture effects in
the human brain. Altern Complement Med 13: 603–616.
9. Zhao ZQ (2008) Neural mechanism underlying acupuncture analgesia. Prog
Neurobiol 85: 355–375.
10. Ulett GA, Han S, Han JS (1998) Electroacupuncture: mechanisms and clinical
application. Biol Psychiatry 44: 129–138.
11. Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358:
55–68.
12. Zhang ZJ, Wang XY, Tan QR, Jin GX, Yao SM (2009) Electroacupuncture for
refractory obsessive-compulsive disorder: a pilot waitlist-controlled trial. J Nerv
Ment Dis 197: 619–22.
13. Huang Y, Gong W, Zou J, Zhao CH (2004) An SCL-90 analysis of scalp
electroacupuncture treatment of major depressive episode. Shanghai Zhen Jiu
Za Zhi 23: 5–7. (in Chinese with English abstract).
14. Li HJ, Zhong BL, Fan YP, Hu HT (2011) Acupuncture for post-stroke
depression: a randomized controlled trial. Zhongguo Zhen Jiu 31: 3–6. (in
Chinese with English abstract).
15. Yeung WF, Chung KF, Tso KC, Zhang SP, Zhang ZJ, et al. (2011)
Electroacupuncture for residual insomnia associated with major depressive
disorder: a randomized controlled trial. Sleep 34: 807–815.
16. Stark P, Hardison CD (1985) A review of multicenter controlled studies of
fluoxetine vs. imipramine and placebo in outpatients with major depressive
disorder. J Clin Psychiatry 46: 53–58.
17. American Psychiatric Association (1994) Diagnostic and statistical manual of
mental disorders. 4th ed. Washington, DC: American Psychiatric Association
Press.
18. Hamilton M (1960) A rating scale for depression. Journal of Neurology
Neurosurgery and Psychiatry 23: 56–62.
19. Guy W (1976) ECDEU assessment manual for psychopharmacology. revised.
Bethesda, MD: US Department of Health, Education, and Welfare.
20. Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, et al. (2003) : A double-blind,
randomized, group-comparative study of the tolerability and efficacy of 6 weeks’
treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin
Psychiat 64: 921–926.
21. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ (2006) Association study of two
serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in
Chinese major depressive disorders. Eur Neuropsychopharmacol 16: 498–503.
22. Han JS (2003) Acupuncture: neuropeptide release produced by electrical
stimulation of different frequencies. Trends Neurosci 26: 17–22.
23. Streitberger K, Kleinhenz J (1998) Introducing a placebo needle into
acupuncture research. Lancet 352: 364–365.
24. Enck P, Klosterhalfen S, Zipfel S (2010) Acupuncture, psyche and the placebo
response. Auton Neurosci 157: 68–73.
25. Lee HC, Chiu HF, Wing YK, Leung CM, Kwong PK, et al. (1994) The Zung
Self-rating Depression Scale: screening for depression among the Hong Kong
Chinese elderly. J Geriatr Psychiatry Neurol 7: 216–220.
26. Fink M, Gutenbrunner C, Rollnik J, Karst M (2001) Credibility of a newly
designed placebo needle for clinical trials in acupuncture research. Forsch
Komplementarmed Klass Naturheilkd 8: 368–372.
27. Allen JJ, Schnyer RN, Chambers AS, Hitt SK, Moreno FA, et al. (2006)
Acupuncture for depression: a randomized controlled trial. J Clin Psychiatry 67:
1665–1673.
28. Andreescu C, Glick RM, Emeremni CA, Houck PR, Mulsant BH (2011)
Acupuncture for the treatment of major depressive disorder: a randomized
controlled trial. J Clin Psychiatry 2011;72: 1129–1135.
29. Zhang WJ, Yang XB, Zhong BL (2009) Combination of acupuncture and
fluoxetine for depression: a randomized, double-blind, sham-controlled trial.
J Altern Complement Med 15: 837–844.
30. Zhou F, Huang D, Xia Y (2009) Neuroanatomical basis of acupuncture points
(Chapter 2). In Xia Y, Wu G, Cao X, Chen J, eds. Acupuncture therapy for
neurological diseases: a neurobiological view, Tsinghua University Press, Beijing,
and Springer-Verlag Berlin, Heidelberg. pp 32–80.
31. Benham A, Johnson MI (2009) Could acupuncture needle sensation be a
predictor of analgesic response? Acupunct Med 27: 65–67.
32. Arbab MA, Delgado T, Wiklund L, Svendgaard NA (1988) Brain stem
terminations of the trigeminal and upper spinal ganglia innervation of the
cerebrovascular system: WGA-HRP transganglionic study. J Cereb Blood Flow
Metab 8: 54–63.
33. Kubota K, Narita N, Ohkubo K, Hosaka K, Nagae K, et al. (1988) Central
projection of proprioceptive afferents arising from maxillo-facial regions in some
animals studied by HRP-labeling technique. Anat Anz 165: 229–251.
34. Foote SL, Bloom FE, Aston-Jones G (1983) Nucleus locus ceruleus: new
evidence of anatomical and physiological specificity. Physiol Rev 63: 844–914.
35. Simpson KL, Altman DW, Wang L, Kirifides ML, Lin RC, et al. (1997)
Lateralization and functional organization of the locus coeruleus projection to
the trigeminal somatosensory pathway in rat. J Comp Neurol 385: 135–147.
36. Simpson KL, Waterhouse BD, Lin RC (1999) Origin, distribution, and
morphology of galaninergic fibers in the rodent trigeminal system. J Comp
Neurol 411: 524–534.
37. Takahashi T, Shirasu M, Shirasu M, Kubo KY, Onozuka M, et al. (2010) The
locus coeruleus projects to the mesencephalic trigeminal nucleus in rats.
Neurosci Res 68: 103–106.
38. Clark L, Chamberlain SR, Sahakian BJ (2009) Neurocognitive mechanisms in
depression: implications for treatment. Annu Rev Neurosci 32: 57–74.
39. Takahashi T (2006) Acupuncture for functional gastrointestinal disorders.
J Gastroenterol 41: 408–417.
40. Kwon YB, Kang MS, Son SS, Kim JT, Lee YH, et al. (2000) Different
frequencies of electroacupuncture modified the cellular activity of serotonergic
neurons in brainstem. Am J Chin Med 28: 435–441.
41. Lee HJ, Lee B, Choi SH, Hahm DH, Kim MR, et al. (2004) Electroacupuncture
reduces stress-induced expression of c-fos in the brain of the rat. Am J Chin Med
32: 795–806.
42. Li A, Wang Y, Xin J, Lao L, Ren K, et al. (2007) Electroacupuncture suppresses
hyperalgesia and spinal Fos expression by activating the descending inhibitory
system. Brain Res 1186: 171–179.
43. Kirkcaldie M, Pridmore S, Reid P (1997) Bridging the skull: electroconvulsive
therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) in
psychiatry. Convulsive Therapy 13: 83–91.
44. van Dijk KR, Scherder EJ, Scheltens P, Sergeant JA (2002) Effects of
transcutaneous electrical nerve stimulation (TENS) on non-pain related
cognitive and behavioural functioning. Rev Neurosci 13: 257–270.
45. Zhang ZJ, Wang XM, McAlonan GM (2011) Neural acupuncture unit (NAU): a
new concept for interpreting effects and mechanisms of acupuncture. eCAM
(accepted, Article ID: 429412).
46. Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complementary
and alternative medicine use among adults: United States, Adv Data 27: 1–19.
47. La Marca R, Nedeljkovic M, Yuan L, Maercker A, Ehlert U (2010) Effects of
auricular electrical stimulation on vagal activity in healthy men: Evidence from a
three-armed randomized trial. Clin Sci (Lond) 118: 537–546.
48. Keller MB, Berndt ER (2002) Depression treatment: a lifelong commitment?
Psychopharmacol Bull 36(S2): 133–141.
Acupuncture for Depression
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29651